OGOlesya A. Goncharova

Olesya A. Goncharova

*This is an algorithmically generated author record based on publicly available information.

Olesya A. Goncharova has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world efficacy and safety of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: Updated data from a Russian observational study

    by Maria I. Volkova, Alexey S. Kalpinskiy, Olesya A. Goncharova, Konstantin V. Menshikov, Olesia A. Stativko, Elena V. Karabina, Aleksandr S. Dergunov, Natalya I. Polshina, Elena N. Alexandrova, Andrey A. Lebedinets, et al.

    Background. A Russian phase IV observational study was initiated to evaluate the efficacy and safety of lenvatinib with pembrolizumab (Len-Pembro) in patients with advanced renal cell carcinoma (RCC) receiving therapy in real-world practice. This article is based on the results of the third analysis conducted with a median follow-up of 23.1 months and reflects data on the efficacy and safety of Len-Pembro in Russian patients. Aim. To evaluate the real-world efficacy and safety of Len-Pembro in patients with advanced RCC with a median follow-up increased to 23.1 months. The primary outcome of the study was progression-free survival (PFS), the secondary outcomes included overall survival (OS), progression-free survival on next-line therapy (PFS2), objective response rate (ORR), duration of response, as well as safety. Materials and methods. The study included data from 165 patients with verified advanced RCC who received Len-Pembro at 36 centers in the Russian Federation from February 05, 2018 to July 30, 2025. The median age was 60 (20–76) years, and 70.3% of the participants were male. Most patients (74.6%) presented with Karnofsky performance score of ≥80%, metachronous metastases (50.9%) of clear cell RCC (93.3%) in 1 organ (75.2%), and had not received any anticancer treatment (91.0%). The IMDC favorable prognosis group included 40 (24.2%), intermediate – 92 (55.8%), and unfavorable prognosis – 33 (20.0%) patients. The median follow-up reached 23.1 (0.5–72.9) months. A total of 110 (66.7%) patients completed Len-Pembro therapy, and 51 (30.9%) patients received next-line treatment. Results. Median PFS reached 25.8 (95% confidence interval – CI 17.0–34.5) months, 23-month PFS – 52.6%; median OS was 39.9 (95% CI 26.9–52.8) months, 23-month OS – 73.1%; median PFS2 was 33.2 (95% CI 23.4–41.1) months, 23-month PFS2 – 66.9%. The ORR was 49.1%, including 3.0% of complete responses, and the disease control rate was 89.1%. The median duration of response reached 29.7 (95% CI 24.9–34.6) months. The incidence of any adverse events (AEs) was 78.8%, severe AEs occurred in 29.1%, fatal AES – in 1.2%, immune-related AEs – 17.0%, severe immune-related AEs – 6.7%. Conclusion. In real-world practice, with increased follow-up duration, the values of PFS, OS, and PFS2 were comparable to those obtained in the registrational study, with a lower ORR and a satisfactory safety profile of the combination of Len-Pembro in advanced RCC.


  • Results of an international, double-blind, randomized, phase III clinical trial to compare the efficacy and safety of a biosimilar pertuzumab (BCD-178) with reference pertuzumab in patients with HER2-positive breast cancer

    by L. G. Zhukova, E. V. Artamonova, S. A. Demidova, К. Д. Пеньков, П. В. Криворотько, O. A. Gladkov, N. V. Kovalenko, N. A. Falaleeva, R. I. Kunafina, L. Yu. Vladimirova, et al.

    Introduction. The increasing need for affordable treatment options for patients with HER2-positive breast cancer necessitates the development of pertuzumab biosimilars to expand access to effective therapies. BCD-178 is a pertuzumab biosimilar that has demonstrated equivalence to reference pertuzumab (RP) based on physicochemical characterization, preclinical in vitro and in vivo and clinical phase I study. The international, multicenter, Phase III clinical trial BCD-178–2/PREFER was conducted to comparatively evaluate the efficacy and safety of BCD-178 and RP in combination with TCHP regimen for neoadjuvant therapy in patients with HER2-positive breast cancer.Objective. To compare the efficacy and safety of the pertuzumab biosimilar BCD-178 and RP when used in a neoadjuvant setting for patients with HER2-positive breast cancer.Methods. The study included female patients aged 18–75 years with histologically confirmed invasive HER2-positive breast cancer and the absence of estrogen receptor (ER) and progesterone receptor (PR) expression. Patients were randomized 1:1 to receive either BCD-178 or RP. The primary endpoint was the proportion of patients achieving a total pathological complete response – tpCR (ypT0/is, ypN 0) based on the conclusion of a central independent review after completion of the neoadjuvant therapy phase.Results. A total of 380 patients were randomized into the study. The proportions of patients achieving tpCR (95 % CI) were not statistically different between the treatment groups (p=0.6521, Cochran–Mantel–Haenszel method). The risk difference (95 % CI) for achieving tpCR between the groups was within the pre-defined equivalence boundaries, demonstrating equivalent efficacy of BCD-178 and RP. The treatment groups were comparable in terms of safety profile, including the incidence of adverse reactions (ARs). The most common (≥10 % of patients) ARs were diarrhea and anemia. The pharmacokinetics and immunogenicity of the drugs were comparable.Conclusions. The study demonstrated comparability between BCD-178 and RP in terms of efficacy, safety, pharmacokinetics, and immunogenicity when used in the neoadjuvant treatment of patients with HER2-positive ER/PR-negative breast cancer.

  • Open Access

    Efficacy of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell carcinoma

    by M. I. Volkova, A. S. Kalpinskiy, О. A. Goncharova, К. V. Menshikov, O. A. Stativko, E. V. Karabina, A. S. Dergunov, N. I. Polshina, E. N. Aleksandrova, A. A. Lebedinets, et al.

    Objective: to re-evaluate the efficacy and safety of lenvatinib with pembrolizumab in unselected Russian renal cell carcinoma (RCC) patients, included in the phase IV study, in a median follow-up extended to 17.1 months. The primary end point was progression-free survival (PFS), secondary end points were overall survival (OS), objective response rate (ORR) and duration of response (DOR), disease control rate (DCR) and its duration, as well as safety.Materials and methods. The study included medical data of 165 patients with verified advanced RCC who received lenvatinib with pembrolizumab in 36 centers of the Russian Federation from 05.02.2018 to 25.07.2024. The median age was 60 (20–76) years, the male to female ratio was 2.3:1. The majority of patients had Karnofsky performance status ³80 % (74.6 %), clear cell RCC (93.3 %) without sarcomatoid differentiation (93.3 %), metachronous metastases (50.9 %) localized in 1 organ (75.2 %), were nephrectomized (63.0 %) and did not receive antitumor therapy (91.0 %). At the time of lenvatinib with pembrolizumab therapy start 40 patients (24.2 %) were classified into International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) favorable prognostic group, 92 (55.8 %) in the intermediate prognostic group, and 33 (20.0 %) in the poor prognostic group. The median follow-up was 17.1 (1.5–72.9) months.Results. The median PFS achieved 24.0 (18.7–29.3) months, 17-month PFS 60.5 %. The median OS was 48.9 (18.5– 79.2) months, 17-month OS – 76.1 %. Objective response was registered in 46.0 % of patients including 2.4 % complete responders; the DCR was 92.1 %. The median DOR was 16.6 (2.1–72.9) months, duration of disease control –14.3 (2.1–72.9) months. Confirmed dynamics of change in the sum of tumor foci diameters was recorded in 152 patients, while the median change was –25 % (from –100 % to +29 %). Any decrease in the sum of tumor foci diameters occurred in 69.1 % of cases. The incidence of any adverse events (AE) was 78.2 %, severe AE – 24.2 %, and serious AE – 9.7 %. Immune-mediated AEs developed in 17.0 % of cases and AE grades 3–4 in 6.7 % of cases. Mortality from AEs was 1.2 %.Conclusion. Compared with the registration study, in real-world clinical practice in patients with advanced RCC the lenvatinib with pembrolizumab provides a lower ORR with comparable PFS and OS rates and demonstrates a satisfactory safety profile.


  • Open Access

    New treatment options for HER2-positive metastatic breast cancer with leptomeningeal metastases

    by A. Yu. Goryainova, S. V. Sharov, O. I. Kirsanova, O. A. Goncharova, R. A. Murashko, А. Ю. Горяинова

    The molecular subtype of breast cancer associated with overexpression of HER2/neu is characterized by more frequent and earlier metastasis to the central nervous system, predetermining an unfavorable prognosis for patients in this category. Patients with secondary brain damage by tumors of any location and histological structure are the most complex group of patients, demonstrating an extremely low level of quality of life, requiring special close monitoring and the development of a personal management algorithm. The development of leptomeningeal lesions doubly complicates the specialist’s task due to the severity of the clinical course and resistance to any therapeutic interventions. The emergence in practice of a new drug a conjugate of the humanized antibody immunoglobulin G1 and the topoisomerase I inhibitor, the exatecan derivative trastuzumab deruxtecan (T-DXd) as an additional therapeutic option is new hope for patients with metastatic breast cancer (mBC), including those with damage to the central nervous system. This article provides an overview of the effectiveness and safety of T-DXd in registration studies, demonstrating the clinical benefit of therapy in a patient with HER2-positive (HER2+) mBC with meningeal involvement in real-world clinical practice.

  • Open Access

    Toxicity and safety of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell cancer: The Russian phase IV observational study

    by Maria I. Volkova, Alexey S. Kalpinskiy, Olesya A. Goncharova, Konstantin V. Menshikov, Elena V. Karabina, Aleksand S. Dergunov, Natalya I. Polshina, Elena N. Alexandrova, Andrey A. Lebedinets, Alexey К. Panov, et al.

    Aim To evaluate the safety and toxicity of lenvatinib with pembrolizumab in unselected patients with advanced renal cell carcinoma (RCC). Materials and methods. The Russian phase IV observational study included 151 patients with advanced RCC who received lenvatinib with pembrolizumab in a standard dose regimen in 36 clinical centers of the Russian Federation. Most patients were diagnosed with clear cell RCC (n=145, 96.0%), with synchronous (n=77,51.0%) metastasesof more than one location (n=111,73.5%), removed primary tumor (n=98, 64.9%) and were classified into intermediate and poor IMDC prognostic groups (n=111, 73.5%). Median follow-up was 9.6 (1—68) months. Results. Any adverse events (AEs) were noted in 109 (72.2%), grade ≥3 AEs-in 26 (17.2%), serious AEs-in 9 (6.0%) of 151 patients. There were no deaths caused by AEs. AEs were an indication for lenvatinib dose reduction in 32 (21.2%), a dose interruptions in lenvatinib treatment in 21 (13.9%), and lenvatinib discontinuation in 2 (1.3%) cases. A dose interruptions in pembrolizumab therapy due to AEs was necessary in 15 (9.9%) cases. Both combination drugs were discontinued due to toxicity in 10 (6.6%) cases. AEs were assessed as immune-mediated in 24 (15.9%) patients (grade 3-4 - n=7, 4.6%) and required the prescription of high doses of glucocorticosteroids in 2 (1.3%) patients. Conclusions. A Russian observational study confirmed the acceptable safety profile of lenvatinib plus pembrolizumab therapy in patients with advanced RCC.


  • Open Access

    Clinical and prognostic characteristics of BRCA1/2-associated breast cancer depending on the type of mutation: estrogen signaling pathway and secondary tumors

    by А. И. Стукань, A. Yu. Goryainova, R. A. Murashko, Z. K. Khachmamuk, O. Yu. Chukhray, S. D. Maksimenko, O. A. Goncharova, E. N. Imyanitov, V. A. Porkhanov, А. Ю. Горяинова, et al.

    Background. Currently, there is growth evidence on prognostic and clinical differences in breast cancer (BC) associated with different types of BRCA1 / 2 mutations. At the same time, a triple negative tumor phenotype is not an absolute pathognomonic sign of BRCA1 / 2-associated cancer, where luminal phenotypes are being detected increasingly. In addition, attention is paid to the significance of estrogen signaling mechanism depending on the surrogate tumor type, including a triple negative phenotype due to alternative mechanisms.Objective: to evaluate significance of BRCA1 / 2-mutations in luminal BC subtypes and multiple tumors.Materials and methods. A prospective study conducted in Clinical Oncology Dispensary No. 1 in Krasnodar included 443 patients with breast cancer who underwent a genetic analysis on BRCA1 / 2 genes status by real-time polymerase chain reaction. In diagnostic cases of luminal phenotype and multiple cancers histological material and blood were sent to the N.N. Petrov Research Institute of Oncology of Ministry of Health of Russia to assess the mutation status of the BRCA1 / 2, ATM, CHEK2, NBS1, PALB2 genes by next-generation sequencing (NGS). Statistical analysis of clinical and morphological parameters correlated with mutational status was performed using the IBM SPSS Statistics v.22 statistical package.Results. An interim analysis of data in April 2022 showed that 71 out of 304 breast cancer patients tested by polymerase chain reaction were found to be carriers of BRCA1 gene mutations. NGS method revealed 20 additional mutations of the BRCA1 / 2 genes: 11 BRCA1 mutations and 9 BRCA2 mutations. PALB2 mutation was also detected in 1 patient, NBS1 mutation – in 3, CHEK2 mutation – in 2, ATM mutation – in 2 patients. Out of 91 BRCA1 / 2-associated breast cancer 21 BRCA1-mutated tumors and 9 tumors with BRCA2-mutation demonstrated luminal phenotypes. The median age of breast cancer disease did not differ in BRCA1- and BRCA2-carriers (42 years versus 40 years, p ˃0.05). BRCA1 mutations are associated with poor differentiation (G3), BRCA2 mutations are associated with G2 (p ˂0.001). The BRCA2 mutation is characterized by a luminal tumor phenotype (p ˂0.001). There was no association of BRCA1 / BRCA2 gene mutations with T and N status (p ˃0.05). Of the 91 cases of BRCA-deficient tumors, 30 (33 %) patients had primary multiple cancer: 27 (90 %) with germinal mutation BRCA1 and 3 (10 %) with germinal mutation BRCA2. Contralateral breast cancer in the presence of germinal mutation BRCA1 was detected in 14 patients. The frequency of primary multiple cancer and contralateral breast cancer detection did not depend on the type of BRCA1 / 2 mutations (p ˃0.05).Conclusion. With the primary multiplicity of the tumor process and the luminal subtype of the tumor, the determination of mutations by polymerase chain reaction in real time is clearly insufficient. It is obvious that the NGS method can identify additional pathogenic mutations that predict the clinical course and indicate the possibility of personalizing therapy and the need to test relatives, including tumors with luminal phenotype and tumors of several localizations.